ERBB2 and breast cancer: Our results contrast with those of the EBCTCG overview(6) (of trials that preceded modern ER/HER2 status testing) showing 10-year reductions in ‘loco-regional recurrence first’ (3.8% vs 20.3%), any first recurrence (34.2% vs 45.7%) and 20-year breast cancer mortality (42.3% vs 50.2%) in 1314 patients with N1 disease, comparable to the 1201 N1 patients in our trial.